Highlights ESMO 2024: O que tivemos em tumores ginecológicos?

Neste vídeo, a Dra Angélica Nogueira, comenta sobre alguns dos mais importantes e que foram apresentados durante a ESMO 2024.

Os estudos comentados foram: 

• 716MO – Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer

• LBA28 – ENGOT-en11/GOG-3053/KEYNOTE-B21: A Phase 3 Study of Pembrolizumab or Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer

• 714MO – Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the Phase 2 TROPION-PanTumor03 study

• 713MO – Nivolumab and Ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial

• LBA29 – Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L)
maintenance: results from PRIMA/ENGOT-OV26/GOG-3012

• LBA30 – ATHENA-COMBO, a phase 3, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)

Para saber mais, acesse o vídeo completo!